Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio [Yahoo! Finance]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Yahoo! Finance
One of several biosimilar value drivers for Sandoz Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Afqlir® (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea®*[1,2]. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD), aiming to prevent disease-related blindness. Afqlir® is one of several biosimilar value drivers for Sandoz and this approval represents a major step in advancing the company's growth strategy. Launch is expected as of Q4 2025. Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, said: "Vision loss significantly affects daily activiti
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Michael L. Baum, Esq. Renowned Advocate Added to Board of Gene Guard Detox, Inc. [Yahoo! Finance]Yahoo! Finance
- Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments [Yahoo! Finance]Yahoo! Finance
- Agrochemicals Market Poised for Significant Growth, Projected to Reach $282.2 Billion by 2028 [Yahoo! Finance]Yahoo! Finance
- Pet Supplements Market to Reach $4.68 Billion by 2031- Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- Watermelon Seeds Market Analysis Report 2025-2030, Featuring Bayer CropScience, Vilmorin & Cie, Syngenta, Origene Seeds, GoldSupplier, Tokita Seed Co., Emerald Seed Company & Hazera [Yahoo! Finance]Yahoo! Finance